![]() Adherix Health launches SMS-first retention platform for GLP-1 treatment programsBehavioral engagement system targets the critical 90-day dropout window with phase-based outreach and automated trigger logic
By: Adherix Health GLP-1 medications have demonstrated strong clinical efficacy, but data consistently shows 40 to 60 percent of patients discontinue treatment within the first year - with the majority of dropout concentrated in the first 90 days, during dose titration when side effects peak and the gap between clinical appointments is longest. For clinic operators, each lost patient represents both a clinical failure and a measurable revenue loss averaging $600 per patient per month. "Clinics are doing everything right clinically but losing patients in the gap between appointments," The Adherix platform (https://adherixhealth.com/ Key platform capabilities include:
The platform is live at adherixhealth.com. Adherix Health is currently accepting applications from metabolic care clinics for its founding partner program (https://adherixhealth.com/ About Adherix Health Adherix Health is a behavioral retention platform purpose-built for GLP-1 treatment programs. The platform delivers phase-based SMS engagement, automated trigger logic, and real-time Drift Correction to help metabolic care clinics identify at-risk patients early and sustain adherence through the critical first 90 days of treatment. Adherix operates as a Business Associate under HIPAA and is designed for clinic operators who need a lightweight, auditable outreach layer without adding staff overhead. Learn more at adherixhealth.com. Media contact Sean Johnson, founder Adherix Health press@adherixhealth.com adherixhealth.com End
|
|